Showing 4371-4380 of 5015 results for "".
- Candela Unveils New Corporate Identity at the 2019 AAD Annual Meetinghttps://practicaldermatology.com/news/candela-unveils-new-corporate-identity-at-the-2019-aad-annual-meeting/2459874/Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- FDA Clears Sculptura Radiation Oncology System from Sensus Healthcarehttps://practicaldermatology.com/news/fda-clears-sculptura-radiation-oncology-system-from-sensus-healthcare/2459884/The FDA has granted market clearance for the Sculptura radiation oncology system from Sensus Healthcare, Inc. With a single treatment during surgery, Sculptura can provide cancer patients and physicians a single radiation treatment at the
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- Remembering a Legend: Vic A Narurkar, MDhttps://practicaldermatology.com/news/remembering-a-legend-vic-a-narurkar-md/2459921/The dermatology community lost a true rock star with the sudden passing of Vic A Narurkar MD, FAAD in late January. Loved by so many, Dr. Narurkar was the Founder of the Bay Area Laser Institute in San Francisco and a past president of the American Society of Cosmetic Derma
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea